Paper Details

  1. Home
  2. Paper Details

Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF<sup>V600</sup> wild-type melanoma progressing on prior anti-programmed death-1 therapy.

Author: AtkinsonVictoria, CaoMaria González, CaroIvor, GuoYu, LongGeorgina V, MedinaTheresa, MenziesAlexander M, RivasAinara Soria, RobertsLouise, SandhuShahneen, SongYuyao, XueCloris, YanYibing

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A phase 1b study of 103 patients with advanced BRAF-mutated melanoma who had progressed on prior anti-PD-1 therapy found that combination therapy with cobimetinib and atezolizumab was effective in achieving objective response rates and disease control rates. The median duration of response was 12.7 months, and the median progression-free survival was 3.8 months. The most common side effects were diarrhea, dermatitis acneiform, and nausea.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the efficacy and safety of cobimetinib plus atezolizumab in the treatment of patients with advanced BRAF PATIENTS AND METHODS: This phase 1b, open-label, international multicentre study enrolled 3 cohorts. Herein, we report on patients in cohorts A and B who had progressed on...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejca.2022.10.019

データ提供：米国国立医学図書館（NLM）

Cobimetinib Plus Atezolizumab: A New Hope for Advanced Melanoma

Melanoma, a particularly aggressive form of skin cancer, is like a relentless desert wind, spreading rapidly and challenging conventional treatment approaches. This study investigates the efficacy and safety of a combination therapy using cobimetinib, a MEK inhibitor, and atezolizumab, an anti-PD-1 antibody, in patients with advanced melanoma who have progressed on prior anti-PD-1 therapy.

The researchers conducted a phase 1b clinical trial, enrolling patients with advanced melanoma who had previously received anti-PD-1 therapy. They found that the combination of cobimetinib and atezolizumab showed promising results, with a significant response rate and disease control rate, suggesting that this combination may be a valuable treatment option for patients with advanced melanoma.

This research offers a potential breakthrough in treating advanced melanoma, providing hope for patients with limited treatment options.

Combating Melanoma: A Multi-Pronged Approach

The study highlights the potential of combining MEK inhibitors and anti-PD-1 antibodies to effectively combat melanoma. It suggests that this approach may be particularly beneficial for patients who have developed resistance to anti-PD-1 therapy.

Navigating the Desert of Cancer Treatment

This research encourages ongoing research and clinical trials to explore new and innovative treatment strategies for melanoma. It underscores the importance of personalized medicine and the development of targeted therapies to address the complex challenges of cancer.

Dr. Camel's Conclusion

The desert of melanoma can be unforgiving, but this research provides a glimmer of hope for patients with advanced disease. The combination of cobimetinib and atezolizumab shows promise as a new treatment option, highlighting the power of targeted therapies to combat this challenging cancer.

Date :
  1. Date Completed 2022-12-20
  2. Date Revised 2023-03-13
Further Info :

Pubmed ID

36455412

DOI: Digital Object Identifier

10.1016/j.ejca.2022.10.019

Related Literature

Article Analysis
・Effects of cobimetinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.